IOncology

Prostate cancer is a malignant tumor occurring in the male reproductive system. Although the incidence in China is lower than in Western countries, it has rapidly increased in recent years, now ranking as the sixth most common male malignancy. With rapid advances in related research, updating prostate cancer treatment guidelines based on the latest evidence-based medicine to suit China's specific context is crucial for early diagnosis, treatment, and improving prognosis. The 2024 CSCO Guidelines Conference is about to take place. "Oncology Frontier" invited Prof. Yao Zhu from Fudan University Cancer Hospital to share key points of the guideline updates.

In the first-line treatment of advanced HER2-positive breast cancer, the combination of pyrotinib and trastuzumab has introduced a new therapeutic model. The complementary mechanisms of large and small molecules have achieved a median progression-free survival (mPFS) of 24.3 months, setting a new standard for first-line treatment of advanced HER2-positive breast cancer. This combination therapy is now recommended by three major domestic guidelines: CSCO BC, CBCS, and ABCC. While the success of this dual-target regimen in advanced stages is clear, its effectiveness in early-stage treatment remains to be seen. Can it provide a new dual-target option for neoadjuvant therapy in HER2-positive breast cancer? In this issue, "Oncology Frontier" invites Prof. Xiaowei Qi to share insights from his report at the South-North Forum titled "Clinical and Translational Research on Pyrotinib Combined with Trastuzumab as Neoadjuvant Therapy for HER2-Positive Breast Cancer," offering an in-depth exploration of this new dual-target regimen in early anti-HER2 therapy.

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) and Chimeric Antigen Receptor T-cell (CAR-T) therapy have become crucial in the treatment of leukemia. However, the effectiveness and safety of these treatments continue to be hot topics of research. Recent breakthrough studies have provided valuable insights, particularly in the treatment of children with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), prevention and monitoring of graft-versus-host disease (GVHD), and management of complications following CAR-T therapy. The 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting, held from April 14 to 17, 2024, in Glasgow, UK, focused on the latest advancements in stem cell transplantation and cellular therapy, pushing forward better clinical outcomes for hematologic patients. At this conference, Professor Shaoyan Hu and her team from the Affiliated Children's Hospital of Soochow University reported on six studies. Oncology Frontier - Hematology Frontier specially invited Professor Shaoyan Hu and her team members to share their research findings on the efficacy and safety of allo-HSCT and CAR-T cell therapy in pediatric leukemia patients in a roundtable discussion format and to provide insightful commentary on these six studies.

Radical cystectomy (RC) and pelvic lymph node dissection (PLND) are standard treatments for muscle-invasive bladder cancer (MIBC), yet distant metastasis remains a challenge for some patients. Exploring perioperative treatment options for MIBC is crucial to improve patient outcomes. At the 39th Annual European Association of Urology (EAU24) Congress in Paris, France, "Oncology Frontier" invited Dr. Zedan Zhang from Professor Kan Gong’s team at Peking University First Hospital to discuss the latest advancements in MIBC perioperative treatment.

In recent years, numerous breakthroughs have been made in the field of renal tumors. The EAU Guidelines Panel continually incorporates new research data and evidence-based medicine to revise and update the EAU guidelines. At the 39th Annual European Association of Urology (EAU24) Congress held in Paris, France, "Oncology Frontier" invited Dr. Ruiyi Deng from Professor Kan Gong's team at Peking University First Hospital to discuss the redefinition of small renal masses (SRMs) and the value of active surveillance.

With the continuous development of medicine and science and technology, the field of breast cancer treatment has seen new breakthroughs. We have witnessed an increasing number of new discoveries and research advancements gradually being applied in clinical practice. These achievements not only enhance the efficiency of breast cancer diagnosis and treatment but also bring more possibilities for breast cancer patients to return to normal life. At the 2024 Southern-Northern Summit, Academician Binghe Xu from the Cancer Hospital of the Chinese Academy of Medical Sciences presented a report on "Progress and Future of Clinical Research in Breast Cancer," sharing current screening and treatment advancements, and experiences from clinical research at the Cancer Hospital of the Chinese Academy of Medical Sciences. This article reviews his insights.

For hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients with no lymph node involvement (N0) and limited high-risk factors, the consensus has been that their risk of recurrence is low, and adjuvant endocrine therapy alone is sufficient. However, with the release of studies like NATALEE, it has become apparent that intensifying treatment for these patients to reduce the risk of recurrence is also necessary. At the 2024 South-North Forum, Prof. Hong Hu from Shenzhen People's Hospital presented a lecture on "Adjuvant Therapy for HR+/HER2- Breast Cancer: Do N0 Patients with Limited High-Risk Factors Need CDK4/6 Inhibitors?" This article reviews the lecture content.

In the vibrant spring of April in Chongqing, from April 19 to April 20, 2024, the "11th Sino-French (International) Advanced Breast Cancer Forum (SFBCS)" was held, co-hosted by several prestigious institutions including the Chinese Anti-Cancer Association's Breast Cancer Committee, the Breast Surgery Expert Group of the Chinese Medical Doctor Association, the Oncology Clinical Research Management Committee of the Chinese Anti-Cancer Association, the Chongqing Clinical Medical Research Federation, the Breast and Thyroid Surgery Department of the First Hospital of Chongqing Medical University, the French Academy of Medical Sciences, and the French Surgical Academy Foundation. Experts from China and abroad gathered to share and exchange knowledge on basic breast cancer research, pathology diagnosis, surgical procedures, and systemic treatment, guiding new directions in the precision medicine era for breast cancer diagnosis and treatment. During the conference, "Oncology Frontier" had the privilege of interviewing Professor Guosheng Ren, the chairman of the conference, who shared insights on the highlights of the forum and the advancements in breast-conserving and reconstructive surgery.

The 11th Sino-French (International) Advanced Breast Cancer Forum (SFBCS) was held in Chongqing on April 19-20, 2024. Experts from around the world shared their knowledge on basic breast cancer research, pathology diagnosis, surgical procedures, and systemic treatment. In the surgical forefront segment, Professor Yongsheng Wang from Shandong Cancer Hospital presented on "Precision Decision-Making in Sentinel Lymph Node Biopsy," discussing clinical practice decisions and patient benefits related to breast cancer sentinel lymph node biopsy (SLNB). "Oncology Frontier" interviewed Professor Wang at the conference, providing insights into the precise selection of patients for SLNB, diagnosis, and clinical management.

For cancer patients, prolonged drug therapy, particularly intravenous treatments, can lead to various inconveniences like infusion reactions and phlebitis. The emergence of new formulations of anticancer drugs not only reduces treatment costs and saves time but also brings convenience to both patients and clinicians. In an era where chronic disease management is becoming more prevalent, how will these new formulations be implemented to help cancer patients move towards recovery? "Oncology Frontier" has invited Professor Jun Ma  from the Harbin Institute of Hematology and Oncology to discuss these issues.